{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:13:29Z","timestamp":1788232409303,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.7759\/cureus.115551","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T02:28:07Z","timestamp":1788229687000},"source":"Crossref","is-referenced-by-count":0,"title":["Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiotherapy for Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Sonam","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satya","family":"Sarangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Riyaz","family":"Lattoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjan","family":"Rajpurohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C. Alepes","family":"Lamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Durga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younis","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial","volume":"40","author":"Versteijne E","year":"2022","unstructured":"Versteijne E, van Dam JL, Suker M, et al.. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022, 40:1220-30. 10.1200\/JCO.21.02233","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01160","article-title":"Management of locally advanced rectal cancer: ASCO guideline","volume":"42","author":"Scott AJ","year":"2024","unstructured":"Scott AJ, Kennedy EB, Berlin J, et al.. Management of locally advanced rectal cancer: ASCO guideline. J Clin Oncol. 2024, 42:3355-75. 10.1200\/JCO.24.01160","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v8.i10.715","article-title":"Current debate in the oncologic management of rectal cancer","volume":"8","author":"Millard T","year":"2016","unstructured":"Millard T, Kunk PR, Ramsdale E, Rahma OE. Current debate in the oncologic management of rectal cancer. World J Gastrointest Oncol. 2016, 8:715-24. 10.4251\/wjgo.v8.i10.715","journal-title":"World J Gastrointest Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00363-8","article-title":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC- 2): a multicentre, open-label, phase 3 randomised trial","volume":"26","author":"Janssen QP","year":"2025","unstructured":"Janssen QP, van Dam JL, van Bekkum ML, et al.. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC- 2): a multicentre, open-label, phase 3 randomised trial. Lancet Oncol. 2025, 26:1346-56. 10.1016\/S1470-2045(25)00363-8","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2019.03.004","article-title":"FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre","volume":"51","author":"Pouypoudat C","year":"2019","unstructured":"Pouypoudat C, Buscail E, Cossin S, et al.. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre. Dig Liver Dis. 2019, 51:1043-9. 10.1016\/j.dld.2019.03.004","journal-title":"Dig Liver Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh P","year":"2023","unstructured":"Ghaneh P, Palmer D, Cicconi S, et al.. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023, 8:157-68. 10.1016\/S2468-1253(22)00348-X","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01685-X","article-title":"Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 \u00d7 2 factorial phase 3 trial","volume":"406","author":"Reni M","year":"2025","unstructured":"Reni M, Macchini M, Orsi G, et al.. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 \u00d7 2 factorial phase 3 trial. Lancet. 2025, 406:2945-56. 10.1016\/S0140-6736(25)01685-X","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.02.037","article-title":"Role of neoadjuvant chemoradiation therapy for resectable and borderline resectable pancreatic adenocarcinoma-a systematic review and meta-analysis","volume":"122","author":"Wu HY","year":"2025","unstructured":"Wu HY, Tsou HH, Lu LS, Lee HL, Chiou JF, Ch'ang HJ. Role of neoadjuvant chemoradiation therapy for resectable and borderline resectable pancreatic adenocarcinoma-a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2025, 122:1257-71. 10.1016\/j.ijrobp.2025.02.037","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021, 88:105906. 10.1016\/j.ijsu.2021.105906","journal-title":"Int J Surg"},{"key":"ref10","unstructured":"NCCN. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines): Pancreatic Adenocarcinoma. (2026). https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1455."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0409-5","article-title":"AHPBA\/SSO\/SSAT consensus conference on resectable and borderline resectable pancreatic cancer: rationale and overview of the conference","volume":"16","author":"Vauthey JN","year":"2009","unstructured":"Vauthey JN, Dixon E. AHPBA\/SSO\/SSAT consensus conference on resectable and borderline resectable pancreatic cancer: rationale and overview of the conference. Ann Surg Oncol. 2009, 16:1725-6. 10.1245\/s10434-009-0409-5","journal-title":"Ann Surg Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji S","year":"2018","unstructured":"Isaji S, Mizuno S, Windsor JA, et al.. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018, 18:2-11. 10.1016\/j.pan.2017.11.011","journal-title":"Pancreatology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-26-515560","article-title":"Contemporary multidisciplinary treatment of borderline-resectable and locally advanced pancreatic adenocarcinoma","volume":"46","author":"Joung RH","year":"2026","unstructured":"Joung RH, Snyder RA. Contemporary multidisciplinary treatment of borderline-resectable and locally advanced pancreatic adenocarcinoma. Am Soc Clin Oncol Educ Book. 2026, 46:e515560. 10.1200\/EDBK-26-515560","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01474-y","article-title":"Highlights from ASCO-GI 2021 from EORTC gastrointestinal tract cancer group","volume":"125","author":"Koessler T","year":"2021","unstructured":"Koessler T, Alsina M, Arnold D, et al.. Highlights from ASCO-GI 2021 from EORTC gastrointestinal tract cancer group. Br J Cancer. 2021, 125:911-9. 10.1038\/s41416-021-01474-y","journal-title":"Br J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy T","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, et al.. Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023, 34:987-1002. 10.1016\/j.annonc.2023.08.009","journal-title":"Ann Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105826","article-title":"Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer","volume":"10","author":"Tai D","year":"2025","unstructured":"Tai D, Conroy T, Lee JJ, et al.. Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer. ESMO Open. 2025, 10:105826. 10.1016\/j.esmoop.2025.105826","journal-title":"ESMO Open"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2014.02.001","article-title":"Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)","volume":"155","author":"Bockhorn M","year":"2014","unstructured":"Bockhorn M, Uzunoglu FG, Adham M, et al.. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014, 155:977-88. 10.1016\/j.surg.2014.02.001","journal-title":"Surgery"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1477-2574.2012.00569.x","article-title":"AHPBA\/SSO\/SSAT sponsored consensus conference on the multidisciplinary treatment of colorectal cancer metastases","volume":"15","author":"Schwarz RE","year":"2013","unstructured":"Schwarz RE, Abdalla EK, Aloia TA, Vauthey JN. AHPBA\/SSO\/SSAT sponsored consensus conference on the multidisciplinary treatment of colorectal cancer metastases. HPB (Oxford). 2013, 15:89-90. 10.1111\/j.1477-2574.2012.00569.x","journal-title":"HPB (Oxford)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0068","article-title":"Defining borderline resectable pancreatic cancer: emerging consensus for an old challenge","volume":"13","author":"Malafa MP","year":"2015","unstructured":"Malafa MP. Defining borderline resectable pancreatic cancer: emerging consensus for an old challenge. J Natl Compr Canc Netw. 2015, 13:501-4. 10.6004\/jnccn.2015.0068","journal-title":"J Natl Compr Canc Netw"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien PA","year":"2009","unstructured":"Clavien PA, Barkun J, de Oliveira ML, et al.. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009, 250:187-96. 10.1097\/SLA.0b013e3181b13ca2","journal-title":"Ann Surg"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo D","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004, 240:205-13. 10.1097\/01.sla.0000133083.54934.ae","journal-title":"Ann Surg"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"4898","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 4898:10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref23","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (2025). Accessed. June 23, 2026: https:\/\/ohri.ca\/en\/who-we-are\/core-facilities-and-platforms\/ottawa-methods-centre\/newcastle-ottawa-scale.."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000002215","article-title":"Can concurrent chemoradiotherapy add meaningful benefit in addition to induction chemotherapy in the management of borderline resectable and locally advanced pancreatic cancer?: a systematic review","volume":"52","author":"Saha A","year":"2023","unstructured":"Saha A, Wadsley J, Sirohi B, et al.. Can concurrent chemoradiotherapy add meaningful benefit in addition to induction chemotherapy in the management of borderline resectable and locally advanced pancreatic cancer?: a systematic review. Pancreas. 2023, 52:e7-20. 10.1097\/MPA.0000000000002215","journal-title":"Pancreas"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2021.12.013","article-title":"Radiation therapy in borderline resectable pancreatic cancer: a review","volume":"172","author":"Turner KM","year":"2022","unstructured":"Turner KM, Delman AM, Kharofa JR, et al.. Radiation therapy in borderline resectable pancreatic cancer: a review. Surgery. 2022, 172:284-90. 10.1016\/j.surg.2021.12.013","journal-title":"Surgery"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-019-1254-8","article-title":"Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1)","volume":"14","author":"Gao S","year":"2019","unstructured":"Gao S, Zhu X, Shi X, et al.. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1). Radiat Oncol. 2019, 14:52. 10.1186\/s13014-019-1254-8","journal-title":"Radiat Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-025-01282-0","article-title":"A randomized controlled trial of stereotactic body radiation therapy versus chemoradiation following induction chemotherapy in borderline resectable and locally advanced pancreatic cancer","volume":"56","author":"Thakur V","year":"2025","unstructured":"Thakur V, Khosla D, Singh G, et al.. A randomized controlled trial of stereotactic body radiation therapy versus chemoradiation following induction chemotherapy in borderline resectable and locally advanced pancreatic cancer. J Gastrointest Cancer. 2025, 56:208. 10.1007\/s12029-025-01282-0","journal-title":"J Gastrointest Cancer"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006910","article-title":"Surgical complications in patients with (borderline) resectable pancreatic cancer after neoadjuvant therapy in the PREOPANC-2 randomized controlled trial","author":"Dekker EN","year":"2025","unstructured":"Dekker EN, Theijse RT, van Dam JL, et al.. Surgical complications in patients with (borderline) resectable pancreatic cancer after neoadjuvant therapy in the PREOPANC-2 randomized controlled trial. Ann Surg. 2025, 10.1097\/SLA.0000000000006910","journal-title":"Ann Surg"},{"key":"ref29","article-title":"Impact of neoadjuvant therapy on borderline resectable pancreatic cancer","volume":"405","author":"Okada K","year":"2020","unstructured":"Okada K, Kawai M, Hirono S. Impact of neoadjuvant therapy on borderline resectable pancreatic cancer. Langenbecks Arch Surg. 2020, 405:487-97.","journal-title":"Langenbecks Arch Surg"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/ans.17151","article-title":"Real world outcomes of neoadjuvant chemotherapy and radiotherapy for borderline resectable pancreatic cancer: a multicentre observational study","volume":"91","author":"Parsonson AO","year":"2021","unstructured":"Parsonson AO, Connolly E, Lee M, et al.. Real world outcomes of neoadjuvant chemotherapy and radiotherapy for borderline resectable pancreatic cancer: a multicentre observational study. ANZ J Surg. 2021, 91:2447-52. 10.1111\/ans.17151","journal-title":"ANZ J Surg"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1744117","article-title":"Surgical and survival outcomes of neoadjuvant IMRT-based chemoradiotherapy versus upfront surgery in borderline resectable pancreatic cancer: a retrospective cohort study","volume":"16","author":"Huang X","year":"2026","unstructured":"Huang X, Yang H, Cai W. Surgical and survival outcomes of neoadjuvant IMRT-based chemoradiotherapy versus upfront surgery in borderline resectable pancreatic cancer: a retrospective cohort study. Front Oncol. 2026, 16:1744117. 10.3389\/fonc.2026.1744117","journal-title":"Front Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/ags3.12726","article-title":"Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement","volume":"8","author":"Akahori T","year":"2024","unstructured":"Akahori T, Terai T, Nagai M, et al.. Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement. Ann Gastroenterol Surg. 2024, 8:151-62. 10.1002\/ags3.12726","journal-title":"Ann Gastroenterol Surg"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2021.12.473","article-title":"Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response","volume":"48","author":"Barrak D","year":"2022","unstructured":"Barrak D, Villano AM, Villafane-Ferriol N, et al.. Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response. Eur J Surg Oncol. 2022, 48:1356-61. 10.1016\/j.ejso.2021.12.473","journal-title":"Eur J Surg Oncol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09149-3","article-title":"Total neoadjuvant therapy for operable pancreatic cancer","volume":"28","author":"Kim RY","year":"2021","unstructured":"Kim RY, Christians KK, Aldakkak M, et al.. Total neoadjuvant therapy for operable pancreatic cancer. Ann Surg Oncol. 2021, 28:2246-56. 10.1245\/s10434-020-09149-3","journal-title":"Ann Surg Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5523","article-title":"Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients","volume":"12","author":"Botta GP","year":"2023","unstructured":"Botta GP, Huynh TR, Spierling-Bagsic SR, Agelidis A, Schaffer R, Lin R, Sigal D. Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients. Cancer Med. 2023, 12:7713-23. 10.1002\/cam4.5523","journal-title":"Cancer Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2020.06.012","article-title":"Respect - a multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer","volume":"20","author":"Weniger M","year":"2020","unstructured":"Weniger M, Moir J, Damm M, et al.. Respect - a multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Pancreatology. 2020, 20:1131-8. 10.1016\/j.pan.2020.06.012","journal-title":"Pancreatology"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.14166","article-title":"Neoadjuvant chemotherapy with chemoradiotherapy for patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma-retrospective review from a tertiary care hospital","volume":"21","author":"Nerwal A","year":"2025","unstructured":"Nerwal A, Yip D, Gananadha S, Shorthouse A, Lee B, Jain A. Neoadjuvant chemotherapy with chemoradiotherapy for patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma-retrospective review from a tertiary care hospital. Asia Pac J Clin Oncol. 2025, 21:392-8. 10.1111\/ajco.14166","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27265","article-title":"Neoadjuvant chemotherapy for pancreatic cancer: quality over quantity","volume":"128","author":"Thalji SZ","year":"2023","unstructured":"Thalji SZ, Aldakkak M, Christians KK, et al.. Neoadjuvant chemotherapy for pancreatic cancer: quality over quantity. J Surg Oncol. 2023, 128:41-50. 10.1002\/jso.27265","journal-title":"J Surg Oncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-21-503","article-title":"Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy","volume":"12","author":"Neibart SS","year":"2021","unstructured":"Neibart SS, Mamidanna S, Chundury A, et al.. Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy. J Gastrointest Oncol. 2021, 12:2557-66. 10.21037\/jgo-21-503","journal-title":"J Gastrointest Oncol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2024.03.012","article-title":"Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: a dual-institution collaborative clinical study","volume":"24","author":"Yamada S","year":"2024","unstructured":"Yamada S, Hashimoto D, Yamamoto T, et al.. Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: a dual-institution collaborative clinical study. Pancreatology. 2024, 24:592-9. 10.1016\/j.pan.2024.03.012","journal-title":"Pancreatology"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2015.1004367","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"54","author":"Mellon EA","year":"2015","unstructured":"Mellon EA, Hoffe SE, Springett GM, et al.. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015, 54:979-85. 10.3109\/0284186X.2015.1004367","journal-title":"Acta Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/522302-total-neoadjuvant-therapy-versus-standard-neoadjuvant-chemoradiotherapy-for-borderline-resectable-pancreatic-cancer-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T02:28:09Z","timestamp":1788229689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/522302-total-neoadjuvant-therapy-versus-standard-neoadjuvant-chemoradiotherapy-for-borderline-resectable-pancreatic-cancer-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.115551","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}